DESONATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DESONATE (DESONATE).
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis.
| Metabolism | Desonide is primarily metabolized in the liver via oxidative and conjugative pathways. The exact enzymes involved are not well characterized. |
| Excretion | Renal (approximately 75% as metabolites, <5% unchanged) and fecal (approximately 25%). |
| Half-life | Terminal half-life is approximately 3-4 hours for desonide; clinically, this supports twice-daily dosing. |
| Protein binding | Desonide is 78-85% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 1.4 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: Systemic bioavailability is low (<5% in healthy skin) but increases with occlusion or damaged skin; oral bioavailability is not clinically relevant as desonide is not administered orally. |
| Onset of Action | Topical: Improvement in pruritus and erythema typically within 24-48 hours. |
| Duration of Action | Topical: Duration of effect is approximately 12 hours with twice-daily application; continuous use beyond 2 weeks should be avoided due to potential for adrenal suppression. |
| Molecular Weight | 416.5 Da |
Apply 0.05% cream, lotion, or ointment topically to affected skin twice daily.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific dose adjustment guidelines for hepatic impairment; use with caution. |
| Pediatric use | Apply 0.05% cream, lotion, or ointment topically to affected area once or twice daily for up to 2 weeks; use smallest amount for shortest duration. |
| Geriatric use | Apply 0.05% cream, lotion, or ointment topically to affected area twice daily; use caution due to increased risk of skin atrophy and systemic absorption. |
| 1st trimester | Topical corticosteroids are generally avoided in first trimester unless benefit outweighs risk; limited data suggest potential association with oral clefts at high potency/doses. |
| 2nd trimester | Use lowest potency and shortest duration; no evidence of major malformations with typical topical use. |
| 3rd trimester | Avoid prolonged use on large areas or under occlusion due to risk of low birth weight and adrenal suppression in neonate. |
Clinical note
Comprehensive clinical and safety monograph for DESONATE (DESONATE).
| Placental transfer | Desonide undergoes minimal systemic absorption from topical application; placental transfer is likely negligible with proper use. Systemic absorption occurs only with prolonged use on large areas or occluded skin. |
| Breastfeeding | Topical application to small areas (<10% body surface) is considered compatible with breastfeeding. Avoid application to breast or nipple area to prevent infant ingestion. Use lowest potency and shortest duration. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to desonide or any component of the formulationViral skin infections (e.g., herpes simplex, vaccinia, varicella)Fungal skin infections (untreated)Bacterial skin infections (untreated)
| Precautions | Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression., Use with caution in patients with skin infections; may mask or worsen infections., Avoid prolonged use on face, intertriginous areas, or under occlusive dressings., Potential growth retardation in pediatric patients., Local adverse reactions including atrophy, striae, and telangiectasia. |
| Food/Dietary | None known; no clinically significant food interactions with topical desonide. |
Loading safety data…
| Lactation Rating | L3 (Limited Data) - Probably compatible with topical use on small areas. |
| Teratogenic Risk | Corticosteroids, including desonide, are classified as Pregnancy Category C. In animal reproduction studies, corticosteroids have been shown to be teratogenic (cleft palate, skeletal abnormalities) at doses equivalent to human doses. There are no adequate and well-controlled studies in pregnant women. First trimester: risk of oral clefts (odds ratio ~3.4) based on epidemiological data with systemic corticosteroids. Second/third trimester: potential for fetal adrenal suppression, intrauterine growth restriction, and low birth weight. Topical application minimizes systemic exposure, but risk increases with extensive use, occlusive dressings, or prolonged treatment. |
| Fetal Monitoring | Monitor for signs of hypothalamic-pituitary-adrenal (HPA) axis suppression in mother with prolonged or extensive use (cosyntropin stimulation test if symptoms). Monitor infant for growth parameters, signs of adrenal suppression (e.g., poor feeding, lethargy) if maternal use is extensive or prolonged. Fetal ultrasound for growth assessment if used in second/third trimester for extended periods. |
| Fertility Effects | No human studies on fertility effects of topical desonide. In animal studies, systemic corticosteroids may impair fertility (e.g., altered estrous cycle, reduced spermatogenesis) at high doses. Topical application with minimal systemic absorption likely has negligible impact on fertility, but data are lacking. |
| Clinical Pearls | Potent topical corticosteroid; limit use to 2 weeks to avoid skin atrophy; avoid occlusion unless directed; do not use on face, groin, or axillae; monitor for systemic absorption if large body surface area treated. |
| Patient Advice | Apply a thin layer to affected skin only, 1-2 times daily as directed. · Do not cover with bandages or wraps unless instructed by your doctor. · Avoid contact with eyes, mouth, open wounds, or mucous membranes. · Do not use for more than 2 consecutive weeks without medical advice. · Wash hands after application unless treating hands. · Notify your doctor if no improvement after 2 weeks or if condition worsens. · Do not share this medication with others. · Keep out of reach of children. |